Searched for: in-biosketch:true
person:bangas01
Bare Metal vs. Drug-Eluting Stents for Calcified Lesion: Findings From the NHLBI PCI Dynamic Registry [Meeting Abstract]
Bangalore, S; Kip, KE; Vlachos, HEA; Selzer, F; Wilensky, RL; Williams, DO; Faxon, DP
ISI:000271831503382
ISSN: 0009-7322
CID: 112333
Management of cocaine-induced chest pain
Chapter by: Frankenberger, Olivier; Sirak, Tseday; Bangalore, Sripal; Greenberg, Henry H
in: Acute coronary syndrome : multidisciplinary and pathway-based approach by Hong, Mun K; Herzog, Eyal [Eds]
London : Springer, c2008
pp. 204-211
ISBN: 1846288681
CID: 232872
Diagnosis and treatment of cardiogenic shock
Chapter by: Palazzo, Angela; Bangalore, Sripal; Tamis-Holland, Jacqueline E; Chorzempa, Amy
in: Acute coronary syndrome : multidisciplinary and pathway-based approach by Hong, Mun K; Herzog, Eyal [Eds]
London : Springer, c2008
pp. 132-143
ISBN: 1846288681
CID: 232852
Diagnosis and treatment of non-ST-segment elevation myocardial infarction
Chapter by: Tamis-Holland, Jacqueline E; Joshi, Sandeep; Palazzo, Angela; Bangalore, Sripal
in: Acute coronary syndrome : multidisciplinary and pathway-based approach by Hong, Mun K; Herzog, Eyal [Eds]
London : Springer, c2008
pp. 60-72
ISBN: 1846288681
CID: 232832
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy
Bangalore, Sripal; Messerli, Franz H; Cohen, Jerome D; Bacher, Peter H; Sleight, Peter; Mancia, Giuseppe; Kowey, Peter; Zhou, Qian; Champion, Annette; Pepine, Carl J
BACKGROUND: In patients with prior myocardial infarction (MI), beta-blockers reduce mortality by 23% to 40%. However, despite this favorable effect, adverse effects limit compliance to this medication. The purpose of the study was to compare a beta-blocker-based strategy with a heart rate-lowering calcium antagonists-based strategy in patients with prior MI. METHODS: We evaluated 7,218 patients with prior MI enrolled in the INternational VErapamil SR-Trandolapril (INVEST) substudy randomized to verapamil-sustained release (SR)- or atenolol-based strategies. Primary outcome was time to first occurrence of death (all-cause), nonfatal MI, or nonfatal stroke. Secondary outcomes included death, total MI (fatal and nonfatal), and total stroke (fatal and nonfatal) considered separately. RESULTS: During the 2.8 +/- 1.0 years of follow-up, patients assigned to the verapamil-SR-based and atenolol-based strategies had comparable blood pressure control, and the incidence of the primary outcome was equivalent. There was no difference between the 2 strategies for the outcomes of either death or total MI. However, more patients reported excellent/good well-being (82.3% vs 78.0%, P = .02) at 24 months with a trend toward less incidence of angina pectoris (12.0% vs 14.3%, adjusted P = .07), nonfatal stroke (1.4% vs 2.0%; P = .06), and total stroke (2.0% vs 2.5%, P = .18) in the verapamil-SR-based strategy group. CONCLUSIONS: In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group
PMID: 18657652
ISSN: 1097-6744
CID: 97808
Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis
Bangalore, Sripal; Wild, David; Parkar, Sanobar; Kukin, Marrick; Messerli, Franz H
OBJECTIVES: This study sought to evaluate the efficacy of beta-blockers (BBs) for primary prevention of heart failure (HF) in patients with hypertension. BACKGROUND: The American College of Cardiology/American Heart Association staging for HF classifies patients with hypertension as stage A HF, for which BBs are a treatment option. However, the evidence to support this is unknown. METHODS: We conducted a MEDLINE/EMBASE/CENTRAL search of randomized controlled trials that evaluated BB as first-line therapy for hypertension with follow-up for at least 1 year and with data on new-onset HF. The primary outcome was new-onset HF. Secondary outcomes were all-cause mortality, cardiovascular mortality, myocardial infarction, and stroke. RESULTS: Among the 12 randomized controlled trials, which evaluated 112,177 patients with hypertension, BBs reduced blood pressure by 12.6/6.1 mm Hg when compared with placebo, resulting in a 23% (trend) reduction in HF risk (p = 0.055). When compared with other agents, the antihypertensive efficacy of BBs was comparable, which resulted in similar but no incremental benefit for HF risk reduction in the overall cohort (risk ratio: 1.00; 95% confidence interval: 0.92 to 1.08), in the elderly (> or =60 years) or in the young (<60 years). Analyses of secondary outcomes showed that BBs confirmed similar but no incremental benefit for the outcomes of all-cause mortality, cardiovascular mortality, and myocardial infarction but increased stroke risk by 19% in the elderly. CONCLUSIONS: In hypertensive patients, primary prevention of HF is strongly dependent on blood pressure reduction. When compared with other antihypertensive agents, there was similar but no incremental benefit of BBs for the prevention of HF. However, given the increased risk of stroke in the elderly, BBs should not be considered as first-line agents for prevention of HF
PMID: 18848139
ISSN: 1558-3597
CID: 112247
Perioperative beta blockade [Letter]
Bangalore, Sripal; Gluud, Christian; Wetterslev, Jorn; Messerli, Franz H
PMID: 18926270
ISSN: 1474-547x
CID: 112246
Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension [Comment]
Messerli, Franz H; Bangalore, Sripal; Julius, Stevo
PMID: 18490538
ISSN: 1524-4539
CID: 112250
Celecoxib and hypertension-insights from the effect of celecoxib on restenosis after coronary angioplasty with a taxus stent trial [Letter]
Bangalore, Sripal; Khianey, Sheila; Messerli, Franz H
PMID: 18359335
ISSN: 0002-9149
CID: 112251
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis
Bangalore, Sripal; Wetterslev, Jorn; Pranesh, Shruthi; Sawhney, Sabrina; Gluud, Christian; Messerli, Franz H
BACKGROUND: American College of Cardiology and American Heart Association (ACC/AHA) guidelines on perioperative assessment recommend perioperative beta blockers for non-cardiac surgery, although results of some clinical trials seem not to support this recommendation. We aimed to critically review the evidence to assess the use of perioperative beta blockers in patients having non-cardiac surgery. METHODS: We searched Pubmed and Embase for randomised controlled trials investigating the use of beta blockers in non-cardiac surgery. We extracted data for 30-day all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, heart failure, and myocardial ischaemia, safety outcomes of perioperative bradycardia, hypotension, and bronchospasm. FINDINGS: 33 trials included 12 306 patients. beta blockers were not associated with any significant reduction in the risk of all-cause mortality, cardiovascular mortality, or heart failure, but were associated with a decrease (odds ratio [OR] 0.65, 95% CI 0.54-0.79) in non-fatal myocardial infarction (number needed to treat [NNT] 63) and decrease (OR 0.36, 0.26-0.50) in myocardial ischaemia (NNT 16) at the expense of an increase (OR 2.01, 1.27-3.68) in non-fatal strokes (number needed to harm [NNH] 293). The beneficial effects were driven mainly by trials with high risk of bias. For the safety outcomes, beta blockers were associated with a high risk of perioperative bradycardia requiring treatment (NNH 22), and perioperative hypotension requiring treatment (NNH 17). We recorded no increased risk of bronchospasm. INTERPRETATION: Evidence does not support the use of beta-blocker therapy for the prevention of perioperative clinical outcomes in patients having non-cardiac surgery. The ACC/AHA guidelines committee should soften their advocacy for this intervention until conclusive evidence is available
PMID: 19012955
ISSN: 1474-547x
CID: 112245